Epidemiological and Morphological Characteristics of Urothelial Bladder Cancer in a Bulgarian and a French Sample of Patients
Bladder carcinoma (BC) is one of the most common malignancies of the urinary system in developed countries, and it is also characterized by a high number of recurrences and progression rates despite multimodal treatment. BC is a biological and clinically heterogeneous tumor with a great propensity of divergent differentiation. Around the world, bladder cancer is responsible for 549.000 new cases и 200.000 deaths each year. In Bulgaria, bladder carcinoma is the 18th most common neoplasia. Our results on 105 proven bladder carcinoma cases confirmed that this tumor arises at 70 years at average (60-90 years), it affects men predominantly and there was no difference regarding the nationality of patients. In conclusion, it remains a diagnostic challenge.
Aydin, A. M., Woldu, S. L., Hutchinson, R. C., Boegemann, M., Bagrodia, A., Lotan, Y., ... & Krabbe, L. M. (2017). Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and therapy, 10, 1487.
Beltran LA. Cheng I, Raspollini MR, Marques RC, Scarpelli M, Gasparrini S, Montironi R. (2017). Variants of Bladder Cancer: The Pathologist's Point of View. European Urology Supplements, 16(12), 210–222.
Battista Di Pierro, G., Gulia, C., Cristini, C., Fraietta, G., Marini, L., Grande, P., ... & Piergentili, R. (2012). Bladder cancer: a simple model becomes complex. Current genomics, 13(5), 395-415.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
Carneiro, B. A., Meeks, J. J., Kuzel, T. M., Scaranti, M., Abdulkadir, S. A., & Giles, F. J. (2015). Emerging therapeutic targets in bladder cancer. Cancer Treatment Reviews, 41(2), 170-178.
Gandomani, H. S., Tarazoj, A. A., Siri, F. H., Karimi Rozveh, A., Hosseini, S., Borujeni, N. N., ... & Salehiniya, H. (2017). Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors. Biomedical Research and Therapy, 4(9), 1638-55.
Gilbert, D. G., McClernon, F. J., Rabinovich, N. E., Sugai, C., Plath, L. C., Asgaard, G., ... & Botros, N. (2004). Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traits. Nicotine & Tobacco Research, 6(2), 249-267.
Hartge, P., Harvey, E. B., Linehan, W. M., Silverman, D. T., Sullivan, J. W., Hoover, R. N., & Fraumeni, J. F. (1990). Unexplained excess risk of bladder cancer in men. JNCI: Journal of the National Cancer Institute, 82(20), 1636-1640.
Horstmann, M., Witthuhn, R., Falk, M., & Stenzl, A. (2008). Gender-specific differences in bladder cancer: a retrospective analysis. Gender medicine, 5(4), 385-394.
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. European urology, 70(1), 93-105.
Ploeg, M., Aben, K. K., & Kiemeney, L. A. (2009). The present and future burden of urinary bladder cancer in the world. World journal of urology, 27(3), 289-293.
Wong, M. C., Fung, F. D., Leung, C., Cheung, W. W., Goggins, W. B., & Ng, C. F. (2018). The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Scientific reports, 8(1), 1-12.
Copyright (c) 2020 Milena Gulinac, Dorian Dikov , Ts. Velikova
This work is licensed under a Creative Commons Attribution 4.0 International License.